Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0024591 (malignant hyperthermia)
 2,353 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

A case of malignant hyperthermia in a Black boy is presented. He developed this condition during repair of a cleft palate, with halothane as the triggering agent. The importance of the high incidence of malignant hyperthermia in patients with certain musculoskeletal abnormalities is stressed. Despite a cool and well air-conditioned theatre, the patient's temperature was 41 degree C when the condition was suspected. At that stage general muscle rigidity was present. The patient was successfully treated with procainamide, sodium bicarbonate and hydrocortisone; surface cooling (with ice packs) was instituted and the stomach was washed out with ice-cold Ringer's solution. Over a period of 14 days serum creatine phosphokinase values decreased from 630 IU (on the day of the incident) to 12 IU. A muscle biopsy showed variation in muscle fibre size. Electron microscopical studies showed myofibrillar disruption and folding of the basement membrane. A modified version of Denborough's technique was used for the in vitro exposure of muscle strips to halothane and suxamethonium. Isometric contraction was measured and recorded. A severe contraction followed the exposure of muscle strips to halothane, which confirmed the diagnosis.
 ...
PMID:[Malignant hyperthermia in a black child. A case report]. 69 25

During the course of a routine H-2 alloimmunization, individual mice within a group of inbred animals produced anti-MHS antibodies of differing specificities. These different antibody populations were directed against various but probably cross-reacting components of complex HLA and H-2 gene products.
 ...
PMID:Individual mice of one inbred strain produce anti-H-2 and anti-HLA antibodies of different specificities. 69 15

We have perfused malignant hyperthermia susceptible and normal isolated pig livers with halothane for one hour. The liver temperatures, oxygen and carbon dioxide tensions, the base deficits and lactate concentrations in blood entering and leaving the liver have been measured at the beginning and at the end of the perfusion. Statistical analysis has shown that there are no significant differences in these parameters between the beginning and the end of the perfusion period or between the normal and the malignant hyperthermia susceptible livers. We conclude, therefore, that the livers of malignant hyperthermia susceptible pigs are either normal or else, if abnormal, the abnormalities are sufficiently benign as to be not measurably expressed.
 ...
PMID:Perfusion of malignant hyperthermia susceptible and normal isolated pig livers with halothane. 69 70

Malignant hyperthermia is a disease resulting from defective cellular membranes, usually presenting as drug-induced pyrexic crises. We describe four patients with life threatening ventricular arrhythmias or chest pain in the absence of pyrexic crises. Three presented with life threatening arrhythmias and the fourth with severe atypical chest pain. Two patients had a family history of multiple sudden deaths. Resting CKs were elevated in three patients while CK-MB was elevated in one. Resting ECGs were abnormal in three. Three patients had recurrent ventricular tachycardia, two had recurrent ventricular fibrillation and multiple cardiac arrests. Cardiac catheterization showed abnormal left ventricular wall motion in two and minimal mitral valve prolapse in one while all had normal coronary arteries. Thallium-201 myocardial imaging demonstrated large perfusion defects in the patient with electrocardiographic Q waves and normal coronary arteries. Myocardial involvement has been demonstrated by clinical, electrocardiographic, hemodynamic, angiographic and myocardial imaging abnormalities. Malignant arrhythmias occurred in these patients in the absence of pyrexic crises or drug admininstration. Abnormal calcium release in the myocardium, as documented in skeletal muscle membranes, may be a unifying concept for the various manifestations described.
 ...
PMID:Cardiac manifestations of malignant hyperthermia susceptibility. 69 60

Malignant hyperthermia is now recognized as a distinct entity in anesthetic practice and can be considered as a pharmacogenetic disease of obscure etiology occuring in man and pigs with a dominant inheritance. A close association with myopathy has been noted. Commonly used muscle relaxants or anesthetic drugs can act as triggering agents in genetically susceptible patients, who develop a real hypermetabolic state, characterized by a rapid rise in body temperature, muscular rigidity, tachycardia and tachypnoea, cyanosis and severe respiratory and metabolic acidosis, the lethality being about 60%. Other clinical, biochemical and histopathological features of this condition are described. The prevention and early diagnosis of this syndrome is very important. Therefore, it is necessary in the preanesthetic evaluation, to obtain information from the patient, with regard to previous anesthetic experiences, and to have a more exact anamnesis in patients with muscular diseases or with other members of the family under suspicion. Some screening methods are described. The prognosis of malignant hyperthermia depends on an early diagnosis. Although the incidence is, fortunately, small, this condition is sufficiently significant and acute in nature to require that anesthesiologist be aware of its clinical pathophysiology and prepared to recognize and treat it promptly. Therefore body temperature should be controlled continuously in all anesthetized patients, particularly in the younger age group and especially in those in which symptoms of muscle rigor have been observed particularly after application of succinylcholine and halothane. A regime of treatment is suggested, based on current concepts of the pathogenesis. It consists in establishing effective and rapid cooling, reversal of tissue hypoxia and correction of respiratory and metabolic acidosis and hyperkalemia. Specific therapy with dantrolene sodium may prove to be an answer to this serious problem.
 ...
PMID:Malignant hyperthermia. 70 24

We report a case of malignant hyperthermia in a man of 41 years during his 13th general anaesthesia. All previous anaesthetics were quite normal. Musculoskeletal abnormalities and increased CPK-levels are to be found in some members of the patient's family. The combined use of suxamethonium and halothane might have caused the development of malignant hyperthermia. As a concept of the aetiology of the syndrome the case history indicates that it may be stress-related.
 ...
PMID:[Malignant hyperthermia during the 13th general anaesthesia (author's transl)]. 71 53

Although malignant hyperthermia is seen most frequently as a complication of orthopedic surgery, most orthopedists have not encountered this commonly fatal problem. A case report and discussion of the inheritable metabolic defect is given. Immediate treatment concepts are discussed.
 ...
PMID:Malignant hyperthermia: a complication of orthopedic surgery. 72 39

A statistical review is given on cases of malignant hyperthermia in Hamburg. The total number of general anesthetics from 1970--1976 was 960 000. 10 cases of malignant hyperthermia have been observed so that a crude estimate of the incidence would be about 1 : 100 000. Some epidemiological aspects of the patients in Hamburg are discussed.
 ...
PMID:[Epidemiological aspects of malignant hyperthermia (author's transl)]. 72 31

Two cases of anaesthesia-induced malignant hyperthermia are reported. One patient died; the other, a 29-years-old woman, recovered without ascertainable after-effects although high temperature persisted for a relatively long time. Suggestions for the early diagnosis of malignant hyperthermia are analysed and the problem of procaine dosage is briefly discussed.
 ...
PMID:[Anaesthesia-induced malignant hyperthermia (author's transl)]. 72 32

The case history is given of a 6-month-old girl who survived an attack of malignant hyperthermia that occurred during the repair of a cleft lip. We believe that this is the youngest such patient reported to date. The current concepts of the mechanisms of excessive heat production and muscular rigidity are presented. The need for constant awareness, early recognition, and prompt and proper treatment on the part of both the operating surgeon and the anesthesiologist are stressed to avoid a fatal outcome. Unfortunately, as yet there is no conclusive, consistent screening test available to identify those who will experience such an episode. Because a patient has once undergone general anesthesia uneventfully does not mean that malignant hyperthermia will not occur during a subsequent procedure or even during use of some amide local anesthetics.
 ...
PMID:Malignant hyperthermia during repair of a cleft lip in a 6-month-old infant, with survival. 72 71


<< Previous 1 2 3 4 5 6 7 8 9 10 Next >>